Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...

More research is needed. If proven effective, gene therapy may displace anti-VEGF injection as the preferred form of treatment for wet AMD. With a better understanding of how age-related macular ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...